Absolute Bioavailability Study With Bexagliflozin

A Phase 1, Single Center, Open-label, Single Period, Non-randomized Study to Determine the Absolute Bioavailability of Bexagliflozin Tablets Following a Single Oral Dose Co-administered With an Intravenous Microtracer Dose of 14C-Bexagliflozin in Healthy Male Subjects

The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.

Inclusion Criteria:

• body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2
• no nicotine and tobacco consumption in the past 3 months
• willing and able to be confined to the clinical research facility as required by the protocol

Exclusion Criteria:

• clinically significant history of allergy to drugs or latex
• history of alcohol or drug dependence in the past 12 months.
• donation of a significant amount of blood in the past 2 months
• willing to use an adequate form of birth control during the study and for 90 days after discharge from clinic
• exposure to investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer